Skip to main content



Page 2 of 39

  1. Content type: Research article

    The clinical benefit of immunotherapeutic approaches against cancer has been well established although complete responses are only observed in a minority of patients. Combination immunotherapy offers an attrac...

    Authors: Guillaume Beyrend, Esmé van der Gracht, Ayse Yilmaz, Suzanne van Duikeren, Marcel Camps, Thomas Höllt, Anna Vilanova, Vincent van Unen, Frits Koning, Noel F. C. C. de Miranda, Ramon Arens and Ferry Ossendorp

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:217

    Published on:

  2. Content type: Research article

    Immune checkpoint inhibitors (ICIs) for solid tumors, including those targeting programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), have shown impressive clinical efficacy,...

    Authors: Jared M. Newton, Aurelie Hanoteau, Hsuan-Chen Liu, Angelina Gaspero, Falguni Parikh, Robyn D. Gartrell-Corrado, Thomas D. Hart, Damya Laoui, Jo A. Van Ginderachter, Neeraja Dharmaraj, William C. Spanos, Yvonne Saenger, Simon Young and Andrew G. Sikora

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:216

    Published on:

  3. Content type: Research article

    Oncolytic viruses preferentially replicate in tumors as compared to normal tissue and promote immunogenic cell death and induction of host systemic anti-tumor immunity. HSV-1 was chosen for further development...

    Authors: Suzanne Thomas, Linta Kuncheria, Victoria Roulstone, Joan N. Kyula, David Mansfield, Praveen K. Bommareddy, Henry Smith, Howard L. Kaufman, Kevin J. Harrington and Robert S. Coffin

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:214

    Published on:

  4. Content type: Research article

    Colorectal cancer (CRC) is one of the most common forms of cancer worldwide. The tumor microenvironment plays a key role in promoting the occurrence of chemoresistance in solid cancers. Effective targets to ov...

    Authors: Dan Wang, Li Yang, Weina Yu, Qian Wu, Jingyao Lian, Feng Li, Shasha Liu, Aitian Li, Zhiang He, Jinbo Liu, Zhenqiang Sun, Weitang Yuan and Yi Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:215

    Published on:

  5. Content type: Case report

    Angiosarcoma is an uncommon endothelial malignancy and a highly aggressive soft tissue sarcoma. Due to its infiltrative nature, successful management of localized angiosarcoma is often challenging. Systemic ch...

    Authors: Vaia Florou, Andrew E. Rosenberg, Eric Wieder, Krishna V. Komanduri, Despina Kolonias, Mohamed Uduman, John C. Castle, Jennifer S. Buell, Jonathan C. Trent and Breelyn A. Wilky

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:213

    Published on:

  6. Content type: Research article

    Pembrolizumab is a potent, humanized, monoclonal anti–programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can res...

    Authors: Marianne J. H. van Vugt, Julie A. Stone, “Rik” H. J. M. M. De Greef, Ellen S. Snyder, Leslie Lipka, David C. Turner, Anne Chain, Mallika Lala, Mengyao Li, Seth H. Robey, Anna G. Kondic, Dinesh De Alwis, Kapil Mayawala, Lokesh Jain and Tomoko Freshwater

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:212

    Published on:

  7. Content type: Research article

    Indoleamine 2,3-dioxygenase 1 (IDO1) is a critical regulator of T cell function, contributing to immune tolerance. Upregulation of IDO1 has been found in many cancer types; however, the regulatory mechanisms a...

    Authors: Qiong Lou, Ruixian Liu, Xiangling Yang, Weiqian Li, Lanlan Huang, Lili Wei, Huiliu Tan, Nanlin Xiang, Kawo Chan, Junxiong Chen and Huanliang Liu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:210

    Published on:

  8. Content type: Research article

    Blocking programmed death-1 (PD-1) is considered to be a promising strategy to improve T cell function, and this is being explored in many ongoing clinical trials. In fact, our knowledge about PD-1 is primaril...

    Authors: Jianshu Wei, Can Luo, Yao Wang, Yelei Guo, Hanren Dai, Chuan Tong, Dongdong Ti, Zhiqiang Wu and Weidong Han

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:209

    Published on:

  9. Content type: Research article

    NKT cells play an important role in anti-tumor immunity. Alpha-galactosylceramide (α-GalCer), a synthetic glycolipid is presented to natural killer T (NKT) cells by most antigen-presenting cells through CD1d m...

    Authors: Sourav Paul, Sushanta Chhatar, Amrita Mishra and Girdhari Lal

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:208

    Published on:

  10. Content type: Research article

    One of the mechanisms by which tumors evade immune surveillance is through shedding of the major histocompatibility complex (MHC) class I chain-related protein A and B (MICA/B) from their cell surface. MICA/B ...

    Authors: Changchun Du, Jack Bevers III, Ryan Cook, T. Noelle Lombana, Kamalakannan Rajasekaran, Marissa Matsumoto, Christoph Spiess, Jeong M. Kim and Zhengmao Ye

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:207

    Published on:

  11. Content type: Commentary

    Tumor mutational burden (TMB) assessment is at the forefront in precision medicine. The TMB could represent a biomarker for immune checkpoint inhibitors (ICIs) responses. Whole exome sequencing (WES) is the go...

    Authors: Hao-Xiang Wu, Zi-Xian Wang, Qi Zhao, Feng Wang and Rui-Hua Xu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:206

    Published on:

  12. Content type: Review

    Management of small cell lung cancer (SCLC) has not changed over the last decades. In more recent years, alterations of DNA repair machinery and other molecular pathways have been identified in SCLC and precli...

    Authors: A. Pavan, I. Attili, G. Pasello, V. Guarneri, P. F. Conte and L. Bonanno

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:205

    Published on:

  13. Content type: Case report

    Late-stage or recurrent intrahepatic cholangiocarcinoma (ICC) patients exhibit poor prognosis due to limited sensitivity to chemotherapy or radiotherapy and coexistence of multiple lesions. Programmed cell dea...

    Authors: Xiaoliang Liu, Jianfei Yao, Lele Song, Sujing Zhang, Tanxiao Huang and Yu Li

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:204

    Published on:

  14. Content type: Case report

    Immune checkpoint inhibitors (ICIs) have now become standard of care treatment for many malignancies. ICIs are associated with unique immune mediated adverse events (irAEs) due to dysregulation of immune activ...

    Authors: Dana Alsaadi, Neil J. Shah, Aline Charabaty and Michael B. Atkins

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:203

    Published on:

  15. Content type: Research article

    Interleukin(IL)-30/IL-27p28 production by Prostate Cancer (PC) Stem-Like Cells (SLCs) has proven, in murine models, to be critical to tumor onset and progression. In PC patients, IL-30 expression by leukocytes...

    Authors: Carlo Sorrentino, Zhinan Yin, Stefania Ciummo, Paola Lanuti, Li-Fan Lu, Marco Marchisio, Matteo Bellone and Emma Di Carlo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:201

    Published on:

  16. Content type: Short report

    Little is known about tumor-associated vasogenic edema in brain metastasis, yet it causes significant morbidity and mortality. Our purpose was to characterize edema in patients treated with anti-PD-1 and to st...

    Authors: Thuy T. Tran, Amit Mahajan, Veronica L. Chiang, Sarah B. Goldberg, Don X. Nguyen, Lucia B. Jilaveanu and Harriet M. Kluger

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:200

    Published on:

  17. Content type: Research article

    Despite major advancements in immunotherapy among a number of solid tumors, response rates among ovarian cancer patients remain modest. Standard treatment for ovarian cancer is still surgery followed by taxane...

    Authors: Christina A. Hartl, Adrian Bertschi, Regina Bou Puerto, Carolin Andresen, Emily M. Cheney, Elizabeth A. Mittendorf, Jennifer L. Guerriero and Michael S. Goldberg

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:199

    Published on:

  18. Content type: Research article

    To profile genomic and epigenomic of a naïve Chinese non-small cell lung cancer (NSCLC) cohort and investigate the association between tumor mutation burden (TMB) and DNA methylation (DNAm) to explore potentia...

    Authors: Liangliang Cai, Hua Bai, Jianchun Duan, Zhijie Wang, Shugeng Gao, Di Wang, Shuhang Wang, Jun Jiang, Jiefei Han, Yanhua Tian, Xue Zhang, Hao Ye, Minghui Li, Bingding Huang, Jie He and Jie Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:198

    Published on:

  19. Content type: Short report

    Strategies to improve activity of immune checkpoint inhibitors are needed. We hypothesized enhanced DNA damage by olaparib, a PARP inhibitor, and reduced VEGF signaling by cediranib, a VEGFR1–3 inhibitor, woul...

    Authors: Alexandra S. Zimmer, Erin Nichols, Ashley Cimino-Mathews, Cody Peer, Liang Cao, Min-Jung Lee, Elise C. Kohn, Christina M. Annunziata, Stanley Lipkowitz, Jane B. Trepel, Rajni Sharma, Lekha Mikkilineni, Margaret Gatti-Mays, William D. Figg, Nicole D. Houston and Jung-Min Lee

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:197

    Published on:

  20. Content type: Research article

    Checkpoint inhibitors (CPI) have revolutionized the treatment of metastatic melanoma, but most patients treated with CPI eventually develop progressive disease. Local therapy including surgery, ablation or ste...

    Authors: Nicholas D. Klemen, Melinda Wang, Paul L. Feingold, Kirsten Cooper, Sabrina N. Pavri, Dale Han, Frank C. Detterbeck, Daniel J. Boffa, Sajid A. Khan, Kelly Olino, James Clune, Stephan Ariyan, Ronald R. Salem, Sarah A. Weiss, Harriet M. Kluger, Mario Sznol…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:196

    Published on:

  21. Content type: Research article

    Transient CD4+ T cell depletion led to the proliferation of tumor-specific CD8+ T cells in the draining lymph node and increased infiltration of PD-1+CD8+ T cells into the tumor, which resulted in strong anti-tum...

    Authors: Kohei Shitara, Satoshi Ueha, Shigeyuki Shichino, Hiroyasu Aoki, Haru Ogiwara, Tetsuya Nakatsura, Toshihiro Suzuki, Manami Shimomura, Toshiaki Yoshikawa, Kayoko Shoda, Shigehisa Kitano, Makiko Yamashita, Takayuki Nakayama, Akihiro Sato, Sakiko Kuroda, Masashi Wakabayashi…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:195

    Published on:

  22. Content type: Research article

    The cancer-associated fibroblast (CAF) population is implicated in immune dysregulation. Here, we test the hypothesis that CAF profiles in pretreatment tumor specimens are associated with response to immune ch...

    Authors: Pok Fai Wong, Wei Wei, Swati Gupta, James W. Smithy, Daniel Zelterman, Harriet M. Kluger and David L. Rimm

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:194

    Published on:

  23. Content type: Short report

    Checkpoint-blockade immunotherapy targeting programmed cell death protein 1 (PD-1) has recently shown promising efficacy in hepatocellular carcinoma (HCC). However, the factors affecting and predicting the res...

    Authors: Yi Zheng, Tingting Wang, Xiaoxuan Tu, Yun Huang, Hangyu Zhang, Di Tan, Weiqin Jiang, Shunfeng Cai, Peng Zhao, Ruixue Song, Peilu Li, Nan Qin and Weijia Fang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:193

    Published on:

  24. Content type: Research article

    Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For patients with non-small cell lung cancer (NSCLC), a potential exposure-response relationship has recently been reported and may arg...

    Authors: Daan P. Hurkmans, Edwin A. Basak, Tanja van Dijk, Darlene Mercieca, Marco W. J. Schreurs, Annemarie J. M. Wijkhuijs, Sander Bins, Esther Oomen-de Hoop, Reno Debets, Markus Joerger, Arlette Odink, Astrid A. M. van der Veldt, Cor H. van der Leest, Joachim G. J. V. Aerts, Ron H. J. Mathijssen and Stijn L. W. Koolen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:192

    Published on:

  25. Content type: Research article

    Glucocorticoid-induced TNFR-related protein (TNFRSF18, GITR, CD357), expressed by T cells, and its ligand (TNFSF18, GITRL), expressed by myeloid populations, provide co-stimulatory signals that boost T cell ac...

    Authors: David M. Richards, Viola Marschall, Katharina Billian-Frey, Karl Heinonen, Christian Merz, Mauricio Redondo Müller, Julian P. Sefrin, Matthias Schröder, Jaromir Sykora, Harald Fricke, Oliver Hill, Christian Gieffers and Meinolf Thiemann

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:191

    Published on:

  26. Content type: Research article

    Innate immune cells such as macrophages are abundantly present within malignant ascites, where they share the microenvironment with ovarian cancer stem cells (CSC).

    Authors: Shreya Raghavan, Pooja Mehta, Yuying Xie, Yu L. Lei and Geeta Mehta

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:190

    Published on:

  27. Content type: Research article

    Cancer immunotherapies are emerging as promising treatment strategies for ovarian cancer patients that experience disease relapse following first line therapy. As such, identifying strategies to bolster anti-t...

    Authors: A. J. Robert McGray, Ruea-Yea Huang, Sebastiano Battaglia, Cheryl Eppolito, Anthony Miliotto, Kyle B. Stephenson, Amit A. Lugade, Gill Webster, Brian D. Lichty, Mukund Seshadri, Danuta Kozbor and Kunle Odunsi

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:189

    Published on:

  28. Content type: Research article

    Immunotherapy has shown remarkable clinical promise in the treatment of various types of cancers. However, clinical benefits derive from a highly inflammatory mechanism of action. This presents unique challeng...

    Authors: Matthew R. Schuelke, Phonphimon Wongthida, Jill Thompson, Timothy Kottke, Christopher B. Driscoll, Amanda L. Huff, Kevin G. Shim, Matt Coffey, Jose Pulido, Laura Evgin and Richard G. Vile

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:188

    Published on:

  29. Content type: Research article

    Micro(mi)RNAs are increasingly recognized as central regulators of immune cell function. While it has been predicted that miRNAs have multiple targets, the majority of these predictions still await experimenta...

    Authors: Martin Hart, Barbara Walch-Rückheim, Lena Krammes, Tim Kehl, Stefanie Rheinheimer, Tanja Tänzer, Birgit Glombitza, Martina Sester, Hans-Peter Lenhof, Andreas Keller and Eckart Meese

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:187

    Published on:

  30. Content type: Hypothesis

    Tumor immunotherapy using gene-modified T cells has already met with considerable success in the treatment of metastatic melanoma and B cell lymphoma. With improving patient prognoses, new questions arise. In ...

    Authors: Cormac Cosgrove, Emilia R. Dellacecca, Joost H. van den Berg, John B. Haanen, Michael I. Nishimura, I. Caroline Le Poole and Hans E. N. Bergmans

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:186

    Published on:

  31. Content type: Research article

    Limitations to current therapies for treating non-Hodgkin B cell lymphoma include relapse, toxicity and high cost. Thus, there remains a need for novel therapies. Oncolytic viral (OV) therapy has become a prom...

    Authors: Minjun Yu, Iris Scherwitzl, Silvana Opp, Aristotelis Tsirigos and Daniel Meruelo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:185

    Published on:

  32. Content type: Position article and guidelines

    Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum,...

    Authors: Ezra E. W. Cohen, R. Bryan Bell, Carlo B. Bifulco, Barbara Burtness, Maura L. Gillison, Kevin J. Harrington, Quynh-Thu Le, Nancy Y. Lee, Rom Leidner, Rebecca L. Lewis, Lisa Licitra, Hisham Mehanna, Loren K. Mell, Adam Raben, Andrew G. Sikora, Ravindra Uppaluri…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:184

    Published on:

  33. Content type: Review

    Tumor mutational burden (TMB), the total number of somatic coding mutations in a tumor, is emerging as a promising biomarker for immunotherapy response in cancer patients. TMB can be quantitated by a number of...

    Authors: Laura Fancello, Sara Gandini, Pier Giuseppe Pelicci and Luca Mazzarella

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:183

    Published on:

  34. Content type: Case report

    In solid organ transplant (SOT) recipients, transplant rejection during immune checkpoint inhibitor (ICI) treatment for cancer is a clinical problem. Donor-derived cell-free DNA (dd-cfDNA) can be detected in b...

    Authors: Daan P. Hurkmans, Jeroen G. H. P. Verhoeven, Kitty de Leur, Karin Boer, Arjen Joosse, Carla C. Baan, Jan H. von der Thüsen, Ron H. N. van Schaik, Ron H. J. Mathijssen, Astrid A. M. van der Veldt and Dennis A. Hesselink

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:182

    Published on:

  35. Content type: Case report

    High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary...

    Authors: Valerie Glutsch, Franziska Grän, Judith Weber, Anja Gesierich, Matthias Goebeler and Bastian Schilling

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:181

    Published on:

  36. Content type: Research article

    Metastasized or unresectable melanoma has been the first malignant tumor to be successfully treated with checkpoint inhibitors. Nevertheless, about 40–50% of the patients do not respond to these treatments and...

    Authors: Andrea Forschner, Florian Battke, Dirk Hadaschik, Martin Schulze, Stephanie Weißgraeber, Chung-Ting Han, Maria Kopp, Maximilian Frick, Bernhard Klumpp, Nicola Tietze, Teresa Amaral, Peter Martus, Tobias Sinnberg, Thomas Eigentler, Ulrike Keim, Claus Garbe…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:180

    Published on:

  37. Content type: Research article

    Immune cells play a key role in cancer progression and treatment. It is unclear whether the clinicopathologic characteristics and blood indexes of colorectal cancer (CRC) patients could predict immune cell con...

    Authors: Guifang Guo, Yixing Wang, Yixin Zhou, Qi Quan, Yijun Zhang, Haohua Wang, Bei Zhang and Liangping Xia

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:179

    Published on:

  38. Content type: Research article

    CD4+ T cells are critical effectors of anti-tumor immunity, but how tumor cells influence CD4+ T cell effector function is not fully understood. Tumor cell-released autophagosomes (TRAPs) are being recognized as ...

    Authors: Yong-Qiang Chen, Peng-Cheng Li, Ning Pan, Rong Gao, Zhi-Fa Wen, Tian-Yu Zhang, Fang Huang, Fang-Yuan Wu, Xi-Long Ou, Jin-Ping Zhang, Xue-Jun Zhu, Hong-Ming Hu, Kang Chen, Yun-Lang Cai and Li-Xin Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:178

    Published on:

  39. Content type: Short report

    We previously reported the results of a multicentric prospective randomized trial of chemo-refractory metastatic breast cancer patients testing the efficacy of two doses of TGFβ blockade during radiotherapy. D...

    Authors: Silvia C. Formenti, Rachael E. Hawtin, Neha Dixit, Erik Evensen, Percy Lee, Judith D. Goldberg, Xiaochun Li, Claire Vanpouille-Box, Dörthe Schaue, William H. McBride and Sandra Demaria

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:177

    Published on:

  40. Content type: Research article

    Recent data suggested a role of gut microbiota and antibiotic use on immune checkpoint inhibitors efficacy. We aimed to evaluate the impact of early use of antibiotic (EUA), blood microbiome and plasmatic citr...

    Authors: Julia Ouaknine Krief, Pierre Helly de Tauriers, Coraline Dumenil, Nathalie Neveux, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Julie Tisserand, Catherine Julie, Jean-François Emile, Thierry Chinet and Etienne Giroux Leprieur

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:176

    Published on:

  41. Content type: Short report

    Immune checkpoint pathways active in Acute Myeloid Leukemia (AML) patients, especially during the course of remission induction chemotherapy, have not been well studied. Although dominant in mediating T cell d...

    Authors: Paola Dama, Marshall Tang, Noreen Fulton, Justin Kline and Hongtao Liu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:175

    Published on:

  42. Content type: Research article

    DNA vaccines against cancer held great promises due to the generation of a specific and long-lasting immune response. However, when used as a single therapy, they are not able to drive the generated immune res...

    Authors: Alessandra Lopes, Sara Feola, Sophie Ligot, Manlio Fusciello, Gaëlle Vandermeulen, Véronique Préat and Vincenzo Cerullo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:174

    Published on:

  43. Content type: Research article

    Non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitors show long lasting responses, but it is hard to predict which patients will profit from this treatment with the currently used mark...

    Authors: Menno Tamminga, Sanne de Wit, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Leon W. M. M. Terstappen and Harry J. M. Groen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:173

    Published on:

  44. Content type: Research article

    Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) like erlotinib are effective for treating patients with EGFR mutant lung cancer; however, drug resistance inevitably emerges. Approaches t...

    Authors: Deborah Ayeni, Braden Miller, Alexandra Kuhlmann, Ping-Chih Ho, Camila Robles-Oteiza, Mmaserame Gaefele, Stellar Levy, Fernando J. de Miguel, Curtis Perry, Tianxia Guan, Gerald Krystal, William Lockwood, Daniel Zelterman, Robert Homer, Zongzhi Liu, Susan Kaech…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:172

    Published on:

  45. Content type: Research article

    Traditional therapies fail to cure most glioblastoma patients and the 5-year survival rate is less than 10%, highlighting need for new therapeutic approaches. The natural killer group 2 member D ligands (NKG2D...

    Authors: Dong Yang, Bin Sun, Hongjiu Dai, Wenxuan Li, Lan Shi, Peixian Zhang, Shirong Li and Xudong Zhao

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:171

    Published on:

  46. Content type: Short report

    Merkel cell carcinoma (MCC) is a rare but clinically aggressive cancer with a high mortality rate. In recent years, antibodies blocking the interactions among PD-1 and its ligands have generated durable tumor ...

    Authors: Jaclyn LoPiccolo, Megan D. Schollenberger, Sumia Dakhil, Samuel Rosner, Osama Ali, William H. Sharfman, Ann W. Silk, Shailender Bhatia and Evan J. Lipson

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:170

    Published on:

  47. Content type: Case report

    Compared to conventional chemotherapy, Immune checkpoint inhibitors (ICI) are known to have a distinct toxicity profile commonly identified as immune-related adverse events (irAEs). These irAEs that are believ...

    Authors: Abdul Rafeh Naqash, Ebenezer Appah, Li V. Yang, Mahvish Muzaffar, Mona A. Marie, Justin D. Mccallen, Shravanti Macherla, Darla Liles and Paul R. Walker

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:169

    Published on:

  48. Content type: Research article

    Natural killer (NK) cells are an emerging new tool for cancer immunotherapy. To develop NK cell therapeutics from peripheral blood mononuclear cells (PBMCs) of healthy donors, substantial expansion of primary ...

    Authors: Yeon Ho Choi, Eun Jin Lim, Se Wha Kim, Yong Wha Moon, Kyung Soon Park and Hee-Jung An

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:168

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:211

Annual Journal Metrics